治疗组合物

By using annexin A5 protein therapy agents to inhibit inflammation and cell death in osteoarthritis, the problem of existing technologies being unable to cure osteoarthritis has been solved, achieving effective prevention and treatment of osteoarthritis.

CN110402149BActive Publication Date: 2026-07-17ANIXIN PHARM CO LTD
View PDF 19 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
ANIXIN PHARM CO LTD
Filing Date
2018-02-08
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current technologies cannot effectively prevent or treat osteoarthritis, especially inflammatory osteoarthritis, and surgery and medication can only manage symptoms, not cure it.

Method used

Using annexin A5 protein as a therapeutic agent, by administering a therapeutically effective amount of annexin A5 protein to subjects, the inflammatory process and cell death in osteoarthritis are inhibited, and joint health is restored.

Benefits of technology

It effectively prevents and treats osteoarthritis, especially inflammatory osteoarthritis, reduces joint inflammation and cell death, and restores joint function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110402149B_ABST
    Figure CN110402149B_ABST
Patent Text Reader

Abstract

本发明涉及用于预防或治疗骨关节炎以及与其相关的病症的新方法、用途和组合物。
Need to check novelty before this filing date? Find Prior Art